[1]. Wang C, Horby PW, Hayden FG GG. A novel coronavirus outbreak of global health concern. Lancet. 2020;395(10223):470–3.
[2]. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020;395(10223):497-506.
[3]. Eftekhari M, Enayati A, Doustimotlagh AH, Farzaei MH, Yosifova Aneva I. Natural Products in Combination Therapy for COVID-19: QT Prolongation and Urgent Guidance. Natural Product Communications. 2021 Sep;16(9):1934578X211032471.
[4]. Eftekhari M, Salehi A, Enayati A. Management of COVID-19 by phytotherapy: A pharmacological viewpoint. Journal of Reports in Pharmaceutical Sciences. 2021 Jan 1;10(1):153.
[5]. Fuzimoto AD, Isidoro C. The antiviral and coronavirus-host protein pathways inhibiting properties of herbs and natural compounds-additional weapons in the fight against the COVID-19 pandemic? J. Tradit. Complement. Med. 2020;10(4):405-19.
[6]. Hajikhani B, Calcagno T, Nasiri MJ, Jamshidi P, Dadashi M, Goudarzi M, Eshraghi AA, FACS, Mirsaeidi M. Olfactory and gustatory dysfunction in COVID‐19 patients: A meta‐analysis study. Physiol. Rep. 2020;8(18):e14578.
[7]. Kannan SP, Ali PS, Sheeza A, Hemalatha K. COVID-19 (Novel Coronavirus 2019)-recent trends. Eur Rev Med Pharmacol Sci. 2020;24(4):2006-11.
[8]. Pathangey G, Fadadu PP, Hospodar AR, Abbas AE. Angiotensin-converting enzyme 2 and COVID-19: patients, comorbidities, and therapies. Am J Physiol Lung Cell Mol Physiol. 2021;320(3):L301-30.
[9]. Puelles VG, Lütgehetmann M, Lindenmeyer MT, Sperhake JP, Wong MN, Allweiss L, Chilla S, Heinemann A, Wanner N, Liu S, Braun F. Multiorgan and renal tropism of SARS-CoV-2. N Engl J Med. 2020;383(6):590-2.
[10]. Tavazzi G, Pellegrini C, Maurelli M, Belliato M, Sciutti F, Bottazzi A, Sepe PA, Resasco T, Camporotondo R, Bruno R, Baldanti F. Myocardial localization of coronavirus in COVID‐19 cardiogenic shock. Eur J Heart Fail. 2020;22(5):911-5.
[11]. Wichmann D, Sperhake JP, Lütgehetmann M, Steurer S, Edler C, Heinemann A, Heinrich F, Mushumba H, Kniep I, Schröder AS, Burdelski C. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med. 2020;173(4):268-77.
[12]. Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, Bikdeli B, Ahluwalia N, Ausiello JC, Wan EY, Freedberg DE. Extrapulmonary manifestations of COVID-19. Nat Med. 2020;26(7):1017-32.
[13]. Bos JM, Hebl VB, Oberg AL, Sun Z, Herman DS, Teekakirikul P, Seidman JG, Seidman CE, Dos Remedios CG, Maleszewski JJ, Schaff HV. Marked up-regulation of ACE2 in hearts of patients with obstructive hypertrophic cardiomyopathy: implications for SARS-CoV-2–mediated COVID-19. Mayo Clin Proc. 2020;95: 1354–1368.
[14]. Liu PP, Blet A, Smyth D, Li H. The science underlying COVID-19: implications for the cardiovascular system. Circulation. 2020;142(1):68-78.
[15]. Onweni CL, Zhang YS, Caulfield T, Hopkins CE, Fairweather DL, Freeman WD. ACEI/ARB therapy in COVID-19: The double-edged sword of ACE2 and SARS-CoV-2 viral docking. Critical Care. 2020;24(1):1-3.
[16]. Caballero J. Considerations for Docking of Selective Angiotensin-Converting Enzyme Inhibitors. Molecules. 2020;25(2):295.
[17]. Din M, Ali F, Waris A, Zia F, Ali M. Phytotherapeutic options for the treatment of COVID‐19: A concise viewpoint. Phytother Res. 2020;1–7.
[18]. Hashem-Dabaghian F, Zimi SA, Bahrami M, Latifi SA, Enayati A, Qaraaty M. Effect of Lavender (Lavandula angustifolia L.) syrup on olfactory dysfunction in COVID-19 infection: A pilot controlled clinical trial. Avicenna Journal of Phytomedicine (AJP). 2021;.
[19]. Monfared M, Eftekhari M, Enayati A, Sabeti M, Amini MH. COVID-19 disease management from the perspective of Traditional Persian Medicine. Journal of Islamic and Iranian Traditional Medicine (JIITM). 2020;11(1):11-22.
[20]. Enayati A, Salehi A, Alilou M, Stuppner H, Mirzaei H, Omraninava A, Khori V, Yassa N. Six new triterpenoids from the root of Potentilla reptans and their cardioprotective effects in silico. Nat Prod Res. 2021;1-9.
[21]. Enayati A, Khori V, Saeedi Y, Yassa N. Antioxidant activity and cardioprotective effect of Potentilla Reptans L. via ischemic preconditioning (IPC). RJP. 2019;6(1):19-27.
[22]. Enayati A, Yassa N, Mazaheri Z, Rajaei M, Pourabouk M, Ghorghanlu S, Basiri S, Khori V. Cardioprotective and anti-apoptotic effects of Potentilla reptans L. root via Nrf2 pathway in an isolated rat heart ischemia/reperfusion model. Life Sci. 2018; 215:216-26.
[23]. Enayati A, Salehi A, Alilou M, Stuppner H, Polshekan M, Rajaei M, Pourabouk M, Jabbari A, Mazaheri Z, Yassa N, Moheimani HR, Khori V. Potentilla reptans L. Postconditioning Protects Reperfusion Injury Via The RISK/SAFE Pathways in an Isolated Rat Heart. DOI: https://doi.org/10.21203/rs.3.rs-148595/v1
[24]. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of computational chemistry (J. Comput. Chem.). 2009;30(16):2785-91.
[25]. Mirzaei H, Shokrzadeh M, Emami S. Synthesis, cytotoxic activity and docking study of two indole-chalcone derivatives. Journal of Mazandaran University of Medical Sciences (J. Maz. Univ. Med. Sci.). 2017;27(154):12-25.
[26]. Emami S, Esmaili Z, Dehghan G, Bahmani M, Hashemi SM, Mirzaei H, Shokrzadeh M, Moradi SE. Acetophenone benzoylhydrazones as antioxidant agents: synthesis, in vitro evaluation and structure-activity relationship studies. Food chemistry (Food Chem.). 2018;268:292-9.
[27]. Yang H, Lou C, Sun L, Li J, Cai Y, Wang Z, Li W, Liu G, Tang Y. admetSAR 2.0: web-service for prediction and optimization of chemical ADMET properties. Bioinformatics (Bioinform.). 2019;35(6):1067-9.
[28]. Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific reports (Sci. Rep.). 2017;7(1):1-3.
[29]. Bernstein KE, Shen XZ, Gonzalez-Villalobos RA, Billet S, Okwan-Duodu D, Ong FS, Fuchs S. Different in vivo functions of the two catalytic domains of angiotensin-converting enzyme (ACE). Current opinion in pharmacology (Curr. Opin. Pharmacol.). 2011;11(2):105-11.
[30]. Li Y, Li XH, Yuan H. Angiotensin II type-2 receptor-specific effects on the cardiovascular system. Cardiovascular diagnosis and therapy (Cardiovasc Diagn Ther.). 2012;2(1):56.
[31]. Forrester SJ, Booz GW, Sigmund CD, Coffman TM, Kawai T, Rizzo V, Scalia R, Eguchi S. Angiotensin II signal transduction: an update on mechanisms of physiology and pathophysiology. Physiological reviews (Physiol. Rev.). 2018;98(3):1627-738.
[32]. Gan W, Ren J, Li T, Lv S, Li C, Liu Z, Yang M. The SGK1 inhibitor EMD638683, prevents Angiotensin II–induced cardiac inflammation and fibrosis by blocking NLRP3 inflammasome activation. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease (BBA-MOL BASIS DIS). 2018;1864(1):1-0.
[33]. Goette A, Lendeckel U. Electrophysiological effects of angiotensin II. Part I: signal transduction and basic electrophysiological mechanisms. Europace. 2008;10(2):238-41.